KRBP News and Press, Kiromic BioPharma Inc. From 03/08/24

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks Smal...

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7 th . This event is sponsored by Zacks Small-Cap Research. Individual investors, inst...

Third Patient Enrolled in Deltacel-01 Completes Treatment Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Ph...

HOUSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief Scientific Officer and Interim Operations Officer...

Second Patient Completed Treatment and Third Patient Dosed in Phase 1 Study Evaluating Deltacel ™ for the Treatment of Non-Small Cell Lung Cancer Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces continued encouragi...

Stabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable early efficacy results from the first patient enrolled in the Phase 1 Deltacel-01...

Company Executives Available to Meet with Investment Professionals January 8-10 in San Francisco Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) , a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMON...

Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...

Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...

Initial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) , a clinical-stage, fully-integrated biotherapeutic...